Catalyst Pharmaceuticals is a biotechnology business based in the US. Catalyst Pharmaceuticals shares (CPRX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $21.12 – an increase of 2.52% over the previous week. Catalyst Pharmaceuticals employs 167 staff and has a trailing 12-month revenue of around $460.5 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $21.12 |
|---|---|
| 52-week range | $13.00 - $24.27 |
| 50-day moving average | $20.97 |
| 200-day moving average | $17.38 |
| Wall St. target price | $31.86 |
| PE ratio | 19.3661 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $1.12 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $21.15 from 2024-11-20
| 1 week (2024-11-14) | -2.49% |
|---|---|
| 1 month (2024-10-21) | 0.62% |
| 3 months (2024-08-21) | 3.32% |
| 6 months (2024-05-21) | 27.95% |
| 1 year (2023-11-21) | 53.93% |
|---|---|
| 2 years (2022-11-21) | 35.93% |
| 3 years (2021-11-19) | 188.93% |
| 5 years (2019-11-21) | 386.21% |
Valuing Catalyst Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalyst Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Catalyst Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Catalyst Pharmaceuticals shares trade at around 19x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Catalyst Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $211.4 million.
The EBITDA is a measure of a Catalyst Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $460.5 million |
|---|---|
| Operating margin TTM | 39.56% |
| Gross profit TTM | $160 million |
| Return on assets TTM | 18.35% |
| Return on equity TTM | 28.29% |
| Profit margin | 31.01% |
| Book value | $5.54 |
| Market Capitalization | $2.7 billion |
TTM: trailing 12 months
We're not expecting Catalyst Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Catalyst Pharmaceuticals's shares have ranged in value from as little as $13 up to $24.27. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catalyst Pharmaceuticals's is 0.755. This would suggest that Catalyst Pharmaceuticals's shares are less volatile than average (for this exchange).
Catalyst Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc. ; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.